Spots Global Cancer Trial Database for A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
Official Title: A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors
Study ID: NCT01714739
Conditions
Study Description
Brief Summary: To assess the safety and tolerability and preliminary anti-tumor activity of lirilumab (BMS-986015) given in combination with nivolumab (BMS-936558) and to identify dose limiting toxicities (DLTs) and the maximally tolerated dose (MTD) of the combination. In addition, to assess the combinations of lirilumab and nivolumab or lirilumab and nivolumab plus ipilimumab (BMS-734016) in subjects with advanced (metastatic and/or unresectable) refractory solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ucsf, San Francisco, California, United States
Florida Cancer Affiliates - Ocala, Ocala, Florida, United States
University Of Chicago Medical Center, Chicago, Illinois, United States
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States
Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Providence Portland Med Ctr, Portland, Oregon, United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
UPMC Eye and Ear Institute, Pittsburgh, Pennsylvania, United States
West Cancer Center, Germantown, Tennessee, United States
Texas Oncology-Central Austin Cancer Center, Austin, Texas, United States
University Of Texas Medical Branch Of Galveston, Galveston, Texas, United States
University Of Washington, Seattle, Washington, United States
Juravinski Cancer Center, Hamilton, Ontario, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Local Institution, Bordeaux, , France
Local Institution, Lyon Cedex 08, , France
Local Institution, Nice Cedex 2, , France
Local Institution, Paris, , France
Institut Gustave Roussy, Villejuif Cedex, , France
IRCCS Istituto Nazionale Tumori Milano, Milano, MI, Italy
Local Institution, Siena, , Italy
Local Institution, Barcelona, , Spain
Local Institution - 0038, Madrid, , Spain
Local Institution, Madrid, , Spain
Kantonsspital Graubuenden, Chur, , Switzerland
Centre Hospitalier Universitaire Vaudois, Lausanne, , Switzerland
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
